MX2013004117A - Formulacion farmaceutica para inhibidores de histona desacetilasa. - Google Patents

Formulacion farmaceutica para inhibidores de histona desacetilasa.

Info

Publication number
MX2013004117A
MX2013004117A MX2013004117A MX2013004117A MX2013004117A MX 2013004117 A MX2013004117 A MX 2013004117A MX 2013004117 A MX2013004117 A MX 2013004117A MX 2013004117 A MX2013004117 A MX 2013004117A MX 2013004117 A MX2013004117 A MX 2013004117A
Authority
MX
Mexico
Prior art keywords
pharmaceutical formulation
histone deacetylase
deacetylase inhibitors
structural formula
values
Prior art date
Application number
MX2013004117A
Other languages
English (en)
Other versions
MX342041B (es
Inventor
Keith A Johnson
Todd W Chappell
Original Assignee
Shape Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shape Pharmaceuticals Inc filed Critical Shape Pharmaceuticals Inc
Publication of MX2013004117A publication Critical patent/MX2013004117A/es
Publication of MX342041B publication Critical patent/MX342041B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una composición farmacéutica que comprende una cantidad terapéuticamente eficaz de un compuesto que es un principio farmacéutico activo (API) representado por la siguiente fórmula estructural. FORMULA, al menos un agente acidificante; y una base transportadora que comprende al menos un disolvente no acuoso farmacéuticamente aceptable. Los valores y valores preferidos de las variables en la fórmula estructural (I) se definen en la presente.
MX2013004117A 2010-10-13 2011-10-13 Formulacion farmaceutica para inhibidores de histona desacetilasa. MX342041B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39285510P 2010-10-13 2010-10-13
PCT/US2011/056148 WO2012051416A1 (en) 2010-10-13 2011-10-13 Pharmaceutical formulation for histone deacetylase inhibitors

Publications (2)

Publication Number Publication Date
MX2013004117A true MX2013004117A (es) 2013-12-02
MX342041B MX342041B (es) 2016-09-12

Family

ID=44903378

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013004117A MX342041B (es) 2010-10-13 2011-10-13 Formulacion farmaceutica para inhibidores de histona desacetilasa.

Country Status (14)

Country Link
US (6) US9255066B2 (es)
EP (1) EP2627316B1 (es)
JP (2) JP6025732B2 (es)
CN (1) CN103347498B (es)
BR (1) BR112013008615B1 (es)
CA (1) CA2814696C (es)
CY (1) CY1121655T1 (es)
HR (1) HRP20191068T1 (es)
MX (1) MX342041B (es)
PT (1) PT2627316T (es)
RS (1) RS58895B1 (es)
RU (1) RU2625758C2 (es)
SI (1) SI2627316T1 (es)
WO (1) WO2012051416A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2975163C (en) * 2014-05-13 2023-09-19 Sam More Formulations for treatment of hyperthyreosis
EP3258908A4 (en) * 2015-02-20 2018-08-22 Pedicis Research LLC Compositions and methods for treatment of skin infections
EP3920911A4 (en) 2019-02-06 2023-03-08 Venthera, Inc. TOPICAL PHOSPHOINONOSITIDE 3-KINASE INHIBITORS
WO2020231800A1 (en) * 2019-05-10 2020-11-19 Encube Ethicals Private Limited Topical antifungal formulation
JP2023538265A (ja) * 2020-08-04 2023-09-07 ベンセラ，インコーポレイティド ホスホイノシチド３－キナーゼ阻害剤の製剤
CN115737549A (zh) * 2022-11-24 2023-03-07 北京鑫开元医药科技有限公司 一种具有hdac抑制活性的注射液及其制备方法和用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6110697A (en) 1995-09-20 2000-08-29 Merck & Co., Inc. Histone deacetylase as target for antiprotozoal agents
US6387673B1 (en) 1997-05-01 2002-05-14 The Salk Institute For Biological Studies Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds
US6376508B1 (en) 2000-12-13 2002-04-23 Academia Sinica Treatments for spinal muscular atrophy
US6706686B2 (en) 2001-09-27 2004-03-16 The Regents Of The University Of Colorado Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
AU2002348474A1 (en) 2001-10-18 2003-04-28 The Salk Institute For Biological Studies Methods of using deacetylase inhibitors to promote cell differentiation and regeneration
US6809118B2 (en) 2002-07-25 2004-10-26 Yih-Lin Chung Methods for therapy of radiation cutaneous syndrome
US8795693B2 (en) * 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
UA89035C2 (ru) * 2003-12-03 2009-12-25 Лео Фарма А/С Эфиры гидроксамовых кислот и их фармацевтическое применение
US20080292616A1 (en) 2005-08-19 2008-11-27 Government Of The United Of America, Represented By The Secretary, Department Of Health And.... Topical Formulations of Histone Deacetylase Inhibitors and Methods Using the Same
JP5409015B2 (ja) * 2006-02-14 2014-02-05 プレジデント アンド フェロウズ オブ ハーバード カレッジ ヒストンデアセチラーゼ阻害剤

Also Published As

Publication number Publication date
US20230190696A1 (en) 2023-06-22
CA2814696C (en) 2019-03-12
BR112013008615A2 (pt) 2016-06-14
US20210038555A1 (en) 2021-02-11
RS58895B1 (sr) 2019-08-30
JP2013539793A (ja) 2013-10-28
US9255066B2 (en) 2016-02-09
US20190175539A1 (en) 2019-06-13
US20170360741A1 (en) 2017-12-21
HRP20191068T1 (hr) 2019-09-06
CN103347498B (zh) 2016-04-13
PT2627316T (pt) 2019-06-11
RU2625758C2 (ru) 2017-07-18
JP2016188261A (ja) 2016-11-04
US20160106700A1 (en) 2016-04-21
JP6025732B2 (ja) 2016-11-16
SI2627316T1 (sl) 2019-06-28
CN103347498A (zh) 2013-10-09
RU2013120914A (ru) 2014-11-20
EP2627316B1 (en) 2019-03-27
CA2814696A1 (en) 2012-04-19
US11607399B2 (en) 2023-03-21
WO2012051416A1 (en) 2012-04-19
MX342041B (es) 2016-09-12
CY1121655T1 (el) 2020-07-31
US20130203847A1 (en) 2013-08-08
EP2627316A1 (en) 2013-08-21
BR112013008615B1 (pt) 2021-05-11
US10258595B2 (en) 2019-04-16

Similar Documents

Publication Publication Date Title
CY1121655T1 (el) Φαρμακευτικη συνθεση για αναστολεις της αποακετυλασης ιστονης
PH12018501807A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseas
WO2010136474A3 (en) Substituted aminobutyric derivatives as neprilysin inhibitors
AU2012259422A8 (en) Solid forms of a pharmaceutically active substance
CA2757418C (en) Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making the same
WO2012030685A3 (en) Indazole derivatives useful as erk inhibitors
TN2012000125A1 (en) Substituted carbamoylmethylamino acetic acid derivatives as novel nep inhibitors
MY156270A (en) Substituted aminopropionic derivatives as neprilysin inhibitors
MX2009008541A (es) Fenilcarbamatos macrociclicos que inhiben el virus de hepatitis c.
WO2011012816A3 (fr) Formulation pharmaceutique
MX2016000675A (es) Derivados de amino-metil-biarilo como inhibidores del factor de complemento d y usos de los mismos.
JO3619B1 (ar) صياغات مثبطة للمناعة
EA201270590A1 (ru) Ингибиторы акт
NO20080220L (no) Formuleringer med hoy medikament belastning og doseringsformer
PH12015501752B1 (en) Substituted bisphenyl butanoic phosphonic acid derivatives as nep inhibitors
WO2010130773A3 (en) Benzoxazolone derivatives as aldosterone symthase inhibitors
WO2012140596A8 (en) Glycoside derivatives and uses thereof
EA201591175A1 (ru) Трициклические соединения в качестве ингибиторов cftr
JO3192B1 (ar) مركب بنزوثيازولون
RS54420B1 (en) FORMULATION CONTAINING PHENYLAMINOPYRIMIDINE DERIVATIVE AS ACTIVE INGREDIENT
MX2016006667A (es) Derivados de pirrolo-pirrolona y su uso como inhibidores.
MX2015010434A (es) Derivados de acido bisfenil-butanoico sustituido como inhibidores de la endopeptidasa neutra (nep), con una mayor eficacia in vivo.
MY160963A (en) Sustained-release therapeutic agent for hypertension and renal dysfunction
MX2020008230A (es) Derivados de ester butanoico sustituido con bisfenilo como inhibidores de nep.
TN2012000617A1 (en) 2,3,5-trisubstituted thiophene compounds and uses thereof

Legal Events

Date Code Title Description
FG Grant or registration